Join Growin Stock Community!

Werewolf therapeutics, inc.HOWL.US Overview

US StockHealthcare
(No presentation for HOWL)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

HOWL AI Insights

HOWL Overall Performance

HOWL AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

HOWL Recent Performance

-5.20%

Werewolf therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

HOWL PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

HOWL Key Information

HOWL Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

HOWL Profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Price of HOWL

HOWL FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

HOWL Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.50
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
52.22
PB Ratio
0.99
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-6335.17%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.50
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
52.22
PB Ratio
0.99
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-6335.17%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is HOWL's latest earnings report released?

    The most recent financial report for Werewolf therapeutics, inc. (HOWL) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating HOWL's short-term business performance and financial health. For the latest updates on HOWL's earnings releases, visit this page regularly.

  • How much debt does HOWL have?

    As of the end of the reporting period, Werewolf therapeutics, inc. (HOWL) had total debt of 37.3M, with a debt ratio of 0.47. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does HOWL have?

    At the end of the period, Werewolf therapeutics, inc. (HOWL) held Total Cash and Cash Equivalents of 66.61M, accounting for 0.84 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is HOWL's EPS continuing to grow?

    According to the past four quarterly reports, Werewolf therapeutics, inc. (HOWL)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of HOWL?

    Werewolf therapeutics, inc. (HOWL)'s Free Cash Flow (FCF) for the period is -15.16M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 21.59% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of HOWL?

    The latest valuation data shows Werewolf therapeutics, inc. (HOWL) has a Price-To-Earnings (PE) ratio of -0.81 and a Price/Earnings-To-Growth (PEG) ratio of 0.14. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.